Why the study?
Treatment adjustment following platelet function testing failed to improve clinical outcomes in the ARCTIC trial despite HPR being considered a predictor of poor ischemic outcome.
Does antiplatelet therapy adjustment based on platelet function testing improve clinical outcomes in patients with high-on-treatment platelet reactivity undergoing PCI?
Does antiplatelet therapy adjustment based on platelet function testing improve clinical outcomes in patients with high-on-treatment platelet reactivity undergoing PCI?
Adjusting antiplatelet therapy based on platelet function testing halves the proportion of high-on-treatment platelet reactivity but does not significantly improve 1-year ischemic outcomes, suggesting HPR is a risk marker rather than a causal risk factor.
Answers are grounded in this paper and cite their sources.
HPR-guided adjustment should not yet change PCI practice; leaves open whether platelet function testing modifies ischemic risk.
BACKGROUND: In the ARCTIC trial (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting), treatment adjustment following platelet function testing failed to improve clinical outcomes. However, high-on-treatment platelet reactivity (HPR) is considered as a predictor of poor ischemic outcome. This prespecified substudy evaluated clinical outcomes according to the residual platelet reactivity status after antiplatelet therapy adjustment. METHODS: test before percutaneous coronary intervention and during the maintenance phase (at 14 days). HPR was defined as platelet reaction unit≥235U. The primary ischemic end point, a composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization and the safety end point of major bleeding were assessed according to the platelet reactivity status. CONCLUSIONS: The proportion of HPR was halved after platelet function testing and treatment adjustment but without significant ischemic benefit at 1 year. HPR seems more as a modifiable risk marker than a risk factor of ischemic outcome. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00827411.
No takes yet. Share an insight, caveat, or question.
Lattuca et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: